Loading
A phase 3 trial of OH2 in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
OH2 Injection in Melanoma is a phase 3 interventional study registered as NCT05868707 by Binhui Biopharmaceutical Co., Ltd., with 340 participants planned, started 2023-03-08 and due to reach its primary completion in 2026-03. Interventions recorded: OH2 and Salvage chemotherapy or best supportive care.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Binhui Biopharmaceutical and the tag pipeline.
Shares Binhui Biopharmaceutical and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/